Correction
This article was originally published in The Gray Sheet
Executive Summary
Gen-Probe: In the Jan. 18, 2010 issue (1p. 14), a "J.P. Morgan Healthcare Conference In Brief" item incorrectly notes that Gen-Probe plans to submit a 510(k) to FDA for its Aptima HPV assay to run on its Tigris system. The company plans to submit a PMA
You may also be interested in...
J.P. Morgan Healthcare Conference In Brief
NxStage Medical: The Lawrenceville, Mass., company is planning to file a 510(k) for a nocturnal indication for its System One home hemodialysis system by March after recently wrapping up a clinical trial, CEO Jeff Burbank said during a Jan. 13 session at the J.P. Morgan Healthcare Conference in San Francisco. System One is indicated for home use, but not specifically nighttime use, and patients usually undergo five to six dialysis sessions per week, the exec noted. The NxStage device is the only home hemodialysis system cleared by FDA, but Baxter, already a leader in peritoneal dialysis, intends to launch its own home-based hemodialysis device in 2011 (1"The Gray Sheet" Sept. 21, 2009)
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.